MGD019 for Cervical Cancer

Overseen By Amir Jazeri, MD

Age: 18+

Sex: Any

Trial Phase: Phase 2

Sponsor: M.D. Anderson Cancer Center

Must not be taking: Immune checkpoint inhibitors, Cytokines

Disqualifiers: Pregnancy, Active infection, Cardiovascular disease, others

No Placebo Group All trial participants will receive the active study treatment (no placebo)

Prior Safety Data This treatment has passed at least one previous human trial

Compensation: Varies

Number of Visits: 1

40 Participants Needed

Trial Summary

Will I have to stop taking my current medications?

The trial protocol does not specify if you need to stop taking your current medications. However, if you are on immunosuppressive therapy or systemic steroids, you may need to stop them before starting the trial.

What is the purpose of this trial?

This trial is testing MGD019, an immunotherapy, to see if it can help the immune system fight advanced cervical cancer in patients who haven't had chemotherapy.

Research Team

Amir Jazeri, MD

Principal Investigator

M.D. Anderson Cancer Center

Eligibility Criteria

This trial is for adults over 18 with confirmed recurrent, metastatic, or persistent cervical cancer who haven't had treatment yet. They must be able to follow the study protocol and have adequate organ function. Women should be post-menopausal or not pregnant and everyone must meet certain blood count criteria. Those vaccinated against COVID-19 need to wait at least 14 days before starting the trial.

Inclusion Criteria

I am willing and able to follow the study's treatment plan and attend all visits.

I received my last COVID-19 vaccine dose more than 14 days ago.

My blood clotting tests are within normal limits, unless I'm on blood thinners.

Exclusion Criteria

I have not had chemotherapy unless it was with radiation.

I have received treatments like immunotherapy before.

I have an autoimmune disease treated with medication in the last 2 years.

Timeline

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Induction Immunotherapy

Participants receive MGD019 to control cervical cancer

6-12 weeks

1 visit per cycle (in-person)

Follow-up

Participants are monitored for safety and effectiveness after treatment

12 weeks

Treatment Details

Interventions

• MGD019

Trial Overview MGD019 is being tested to see if it can control advanced cervical cancer in patients who are receiving their first treatment. The study will monitor how well this drug works and its safety in participants meeting specific health criteria.

Participant Groups

Group I: Lorigerlimab Experimental Treatment 1 Intervention

Participants will receive Lorigerlimab by vein over about 30 minutes on Day 1 of each cycle

Who Is Running the Clinical Trial?

M.D. Anderson Cancer Center

Lead Sponsor

Trials

3,107

Recruited

1,813,000+

MacroGenics

Industry Sponsor

Trials

51

Recruited

5,400+